Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated HBV Vaccination in Patients Requiring Anti-CD20
NCT04519710Completed
- Sponsor
- Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of hepatitis B vaccine recombinant in hepatitis B (HBV) (3 arms), sponsored by Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida. Primary endpoint: Specific anti-HBV vaccine response (Anti-HBs > 10 IU/l) at 13 months. Started Sep 2020; status: completed.
02
Drugs
hepatitis B vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04519710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519710.